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Abstract
The fungus Cryptococcus is a major cause of meningoencephalitis in HIV-infected as well
as HIV-uninfected individuals with mortalities in developed countries of 20% and 30%, re-
spectively. In HIV-related disease, defects in T-cell immunity are paramount, whereas there
is little understanding of mechanisms of susceptibility in non-HIV related disease, especially
that occurring in previously healthy adults. The present description is the first detailed immu-
nological study of non-HIV-infected patients including those with severe central nervous
system (s-CNS) disease to 1) identify mechanisms of susceptibility as well as 2) understand
mechanisms underlying severe disease. Despite the expectation that, as in HIV, T-cell im-
munity would be deficient in such patients, cerebrospinal fluid (CSF) immunophenotyping,
T-cell activation studies, soluble cytokine mapping and tissue cellular phenotyping demon-
strated that patients with s-CNS disease had effective microbiological control, but displayed
strong intrathecal expansion and activation of cells of both the innate and adaptive immunity
including HLA-DR+ CD4+ and CD8+ cells and NK cells. These expanded CSF T cells were
enriched for cryptococcal-antigen specific CD4+ cells and expressed high levels of IFN-γ as
well as a lack of elevated CSF levels of typical T-cell specific Th2 cytokines – IL-4 and IL-
13. This inflammatory response was accompanied by elevated levels of CSF NFL, a marker
of axonal damage, consistent with ongoing neurological damage. However, while tissue
macrophage recruitment to the site of infection was intact, polarization studies of brain biop-
sy and autopsy specimens demonstrated an M2 macrophage polarization and poor phago-
cytosis of fungal cells. These studies thus expand the paradigm for cryptococcal disease
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susceptibility to include a prominent role for macrophage activation defects and suggest a
spectrum of disease whereby severe neurological disease is characterized by immune-me-
diated host cell damage.
Author Summary
Cryptococcus is an important cause of fungal meningitis with significant mortality globally.
Susceptibility to the fungus in humans has been related to T-lymphocyte defects in HIV-
infected individuals, but little is known about possible immune defects in non HIV-in-
fected patients including previously healthy individuals. This latter group also has some of
the worst response rates to therapy with almost a third dying in the United States, despite
available therapy. Here we conducted the first detailed immunological analysis of non-
HIV apparently immunocompetent individuals with active cryptococcal disease. In con-
trast to HIV-infected individuals, these studies identified a highly activated antigen-pre-
senting dendritic cell population within CSF, accompanied by a highly active T-
lymphocyte population with potentially damaging inflammatory cytokine responses. Fur-
thermore, elevated levels of CSF neurofilament light chains (NFL), a marker of axonal
damage in severe central nervous system infections suggest a dysfunctional role to this
acute inflammatory state. Paradoxically, CSF macrophage proportions were reduced in pa-
tients with severe disease and biopsy and autopsy samples identified alternatively activated
tissue macrophage populations that failed to appropriately phagocytose fungal cells. Our
study thus provides new insights into the susceptibility to human cryptococcal disease and
identifies a paradoxically active T-lymphocyte response that may be amenable to adjunc-
tive immunomodulation to improve treatment outcomes in this high-mortality disease.
Introduction
Cryptococcus neoformans is an important cause of fatal meningoencephalitis in both those im-
munosuppressed from transplant conditioning or HIV/AIDS, as well as in previously healthy
individuals. While AIDS-related cases represent the bulk of disease burden worldwide [1] with
mortality approaching 60% in the developing world [2,3] and 20% in the developed world [4],
non-HIV related cryptococcosis is a significant source of mortality and morbidity in the devel-
oped world, accounting for approximately a third of cases [5], with up to 30% mortality despite
optimal therapy [4,6]. These mortality figures are derived from unselected cohorts in routine
clinical settings and not clinical trials. In HIV-related disease where fungal burdens are high
and cellular immunity low, recent approaches have sought to improve microbiological clear-
ance from the CSF, an important prognostic marker [7]. These strategies have combined fungi-
cidal drugs [8] or adjunctive cytokines such as interferon-γ (IFN-γ) [9,10]. The latter approach
seeks to boost Th1-polarizing immunity, an immunological marker of survival during initial
therapy [11]. In non-HIV-related disease, CSF fungal loads and effective microbiological clear-
ance have similarly been associated with favorable outcomes [12]. However, little data is avail-
able regarding the immune milieu of these patients that could guide treatment, especially in
severe or refractory cases. This has led to varying approaches for severe disease, including the
use of immune intensifying regimens such as adjunctive IFN-γ [13], or immune-suppressive
therapies such as steroids in the case of infections with C. gattii in previously healthy individu-
als [14]. Indeed, having too much or too little of a host immune response to infection may
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cause significant pathology [15,16]. Steroids have also been used in HIV-related cryptococcal
meningoencephalitis with or without immune reconstitution syndrome (cIRIS), an aggravated
paradoxical immune response to the pathogen in the setting of microbiologic control after res-
toration of T-cell activity from anti-retroviral therapy [17–19]. cIRIS is characterized by in-
creases in immunoregulatory natural killer cells and IFN-γ-dependent factors such as
monocyte attractant CXC motif chemokine 10 [20]. A clinical syndrome similar to cIRIS has
also been reported in transplant recipients after reductions in immunoconditioning [21].
cIRIS-like syndromes are particularly problematic in cryptococcal meningitis, as the closed
compartment of the brain within the skull allows little expansion with inflammation or cerebral
edema. However, it is unclear whether the immunological response in cIRIS-like syndromes is
similar in other cryptococcal patients.
Thus, given the controversies in management of severe cases of cryptococcal meningitis and
an unexpected response to steroids in 2 sentinel cases under our care, more detailed, host-spe-
cific immune characterizations were sought to suggest a basis for rational treatment design in
this complex disease. To this end, we conducted the first detailed immunological analysis of
soluble and cellular responses to Cryptococcus in both blood and CSF in a consecutive cohort
of non-HIV, non-transplant individuals with no comorbidities or iatrogenic immunosuppres-
sion who developed severe central nervous system disease (s-CNS). Despite minimal doses of
steroids for maintenance of mental status that may have declined due to cerebral edema,
immunophenotyping of s-CNS patients during therapy demonstrated a CNS compartmental-
ized, marked increase in activated T cell and NK cell populations, accompanied by elevated sol-
uble IFN-γ, interferon-generating cytokines IL-18, and interferon-induced chemokines
CXCL10, as compared to a cohort having non-CNS disease (non-CNS) or healthy donors
(HD). Ex vivo T-cell activation with cryptococcal antigen-loaded dendritic cells (DCs) also
demonstrated a compartmentalized Th1 response with increased CD4+ and CD8+ IFN-γpro-
duction, thus providing a mechanism for the clinical deterioration and response to steroids.
However, the present studies also demonstrated reduced monocyte and myeloid dendritic cells
in the CSF and an M2 bias in tissue-infiltrating macrophages on examination of biopsy and au-
topsy specimens from patients with s-CNS disease, suggesting downstream defects in myeloid
activation. These data thus identify a paradoxical Th1-biased CSF immune response in severe
CNS cryptococcal disease after microbiological control, suggesting further study to investigate
the role for adjunctive T-cell immunosuppressive therapy in this high mortality disease.
Results
Steroid-responsiveness of s-CNS disease in two previously healthy
individuals provides a rationale for immunophenotyping studies
While the severity of the clinical conditions precluded randomization to steroid treatment, clin-
ical responses to steroids (prednisone 1 mg/kg/d) were observed in two patients who developed
deteriorating mental status despite effective fungicidal therapy and negative CSF fungal cul-
tures. This provided a rationale for detailed immune studies, subsequently performed on 17
consecutive patients with CNS disease (Table 1) defined by positive cryptococcal cultures or an-
tigens at the time of diagnosis. The subgroup excluded patients with previous immunosuppres-
sion or known risk factors for cryptococcal disease such as idiopathic CD4 lymphopenia [22].
The first steroid-responsive patient was a 58 year-old male who presented with dizziness,
hearing loss and a left-sided facial droop. CSF cultures grew C. neoformans, identified on L-
canavanine glycine bromothymol blue (CGB) media. The patient was treated with 6 weeks of
intravenous amphotericin B lipid complex and flucytosine followed by fluconazole, but re-
quired placement of a ventriculoperitoneal shunt for deteriorating mental status and
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Table 1. Patient characteristics of 17 severe central nervous system cryptococcosis (s-CNS) cases
and 6 non-CNS cases.*
Variable s-CNS (n = 17) non-CNS (n = 6)
Median Age (years) 54 [IQR:44.0–59.0] 47.5 [IQR:35.3–56.0]
Female 7 4
Race:
White 12 5
Black 1 0
Hispanic 1 0
Asian 3 1
Geographic Region†:
Northeast 2 2
Midwest 0 0
South 9 3
Paciﬁc Northwest 2 0
West 4 1
Antecedent Comorbidities:
Diabetes mellitus 3 1
Hepatitis 1 1
Atopic Dermatitis/Asthma/Sinusitis 4 1
Thyroid disorder 2 1
Obesity 2 2
Smoking 2 1
Seizure disorder 1 0
Mucosal infection 2 0
None 5 1
Cryptococcal Species:
C. gattii 5 1
C. neoformans 10 4
Unconﬁrmed 2 1
Median CD4+ Tcell count, cells/μl 526[IQR:324.0–
828.6]
1241.5[IQR:862.2–
1568.2]
Median CD8+ Tcell count, cells/μl 296[IQR:141.0–
367.1]
392.0[IQR:337.8–487.4]
Median CSF Leukocyte Count per mm3 34 [IQR:13.0–57.3] 2 [IQR: 0.5–2.0]
Median CSF Cryptococcal Antigen titer 1:64[0–1:1024] negative
Median Serum Cryptococcal Antigen titer 1:64 [0–1:32768] 0 [0–1:64]
Median Serum C-reactive Protein (mg/L) 3.78[IQR:1.39–8.18] 3.15[IQR:1.68–5.01]
Median Time from Symptom Onset to Diagnosis (days) 61 [IQR:18.0–133] 92 [IQR:50–146.5]
Median Time from Diagnosis to Study (days) 145[IQR:113.0–
400.0]
798.5[IQR:666.5–
1336.2]
Median Prednisone equivalent dose at Study (mg) 2.5 [IQR:0–30] 0
Shunt 12 N/A
Median Time of Last Dose of Amphotericin B until Study
(days)
30 [IQR: 5.5–337] N/A
Antifungal at time of Study:
Lipid Amphotericin B 2 0
Voriconazole 5 0
Fluconazole 10 3
None 0 3
(Continued)
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persistently elevated intracranial pressures. The patient was then transferred to the NIH clinical
center, having a GCS of 13. Brain MRI scanning showed increased signal intensity (bright sig-
nal) on enhanced fluid attenuation inversion recovery (FLAIR) imaging within the sulci, espe-
cially the right central sulcus (Fig 1A). This patient was treated on day 1 with liposomal
amphotericin B and flucytosine without improvement over a 2 month period with 10 day GCS
mean scores ranging from 11–13, prompting a trial of recombinant interferon-γ 1b (red arrow
in Fig 1A), but the patient developed hypersomnolence with significant worsening of mean
GCS over the ensuing 10 days (pre: 12.2 +/-0.3 (SEM), N = 23; post: 10.6 +/- 0.3, N = 19;
p = 0.001). As a result, recombinant interferon-γ 1b was discontinued and corticosteroids
(prednisone 1 mg/kg/d) were added, after a 1 week ‘washout’ of IFN-γ, to the standing regimen.
After this addition, the patient showed progressive improvement in mental status over the next
40 day period (10 day GCS, pre: 10.6 +/-0.3 (SEM), N = 19; 40 day post: 13.7 +/- 0.4, N = 21;
p< 0.001) and normalization of GCS in 60 days (Fig 1B). Unfortunately, this patient developed
residual bilateral cranial nerve VII and VIII palsies prior to steroid therapy, resulting in corneal
scarring with consequential blindness and deafness, and gait disturbance and urinary retention
from cryptococcal cauda equina syndrome.
The second patient was a 46 year-old female fromWashington State who presented with in-
termittent fevers, worsening headaches, and altered mental status. MRI of the brain with gado-
linium demonstrated multiple enhancing mass lesions in the left basal ganglia with the largest
measuring approximately 3.5 x 2.8 centimeters. Adjacent smaller but more intensely enhancing
lesions were seen in the left basal ganglia as well as throughout the brain, including multiple
smaller lesions in the right posterior frontal lobe, left insula, right thalamus, left temporal lobe
and left cerebellum (Fig 1B). The left basal ganglia lesions were associated with surrounding
edema, best appreciated on FLAIR images as bright signal around the lesions, with secondary
mass effect and slight impingement on the left lateral ventricle. Chest CT revealed an 8-cm
right mid-lung mass, which was biopsied and grew C. gattii, genotype AFLP6A/VGIIa [23],
Table 1. (Continued)
Variable s-CNS (n = 17) non-CNS (n = 6)
Signs and Symptoms at Time of Study:
Fever 1 2
Mental Status Changes 7 0
Malaise 5 0
Headache 5 1
Visual Deﬁcits 6 0
Sensorineural hearing loss 4 0
Balance problems 5 0
Focal Neurologic Signs 3 0
Nausea/Vomiting 1 0
Chronic Cough 0 0
Chest/Back Pain 1 2
Dyspnea 1 1
Asymptomatic 0 1
* = values at time of analysis
† = categories modiﬁed from Agency for Healthcare Research and Quality
N/A = not applicable
IQR = inter-quartile range
doi:10.1371/journal.ppat.1004884.t001
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consistent with the predominant outbreak strain found in the Pacific Northwest [24] and
serum testing subsequently identified a functional anti-GMCSF autoantibody measured as pre-
viously described [25]. She was begun on liposomal amphotericin B, flucytosine and predni-
sone 50mg/d with improvement in mental status and MRI imaging at 24 days, which
demonstrated decreased edema (decreased bright signal on FLAIR) in association with the left
basal ganglia lesions and reduction in left lateral ventricular obstruction (Fig 1B, Day 24 and S1
Fig). Steroids were discontinued on day 24 to minimize possible immune suppression at the
outside hospital and the patient’s status again deteriorated by day 34, prompting intensive care
unit admission. Of note, the patient continued treatment with amphotericin B, remaining with
negative CSF fungal cultures. Repeat MRI imaging showed recurrence of edema surrounding
the left basal ganglia lesions with increased mass effect on the left lateral ventricle and slight
midline shift (Fig 1B, Day 34). After consultation with the NIH, dexamethasone equivalent to
prednisone 50mg/d was again added to the amphotericin B regimen with improvement in
Fig 1. Steroid-responsiveness of s-CNS cryptococcosis in previously healthy patients. A) Patient 1: Left panel, Enhanced T1 (upper row) and FLAIR-
weighted MRI images (lower row) pre-steroid (pre) and 22 days post (22 d post) steroid treatment. White arrowheads point to increased (bright) signal within
the sulci on enhanced FLAIR imaging. Right panel, Ten day average Glasgow coma score (GCS) (•) +/- SEM (N > 20 for each value) and CSF cryptococcal
latex antigen (*). Red arrow indicates time of initiation of treatment with IFN-γand black arrow indicates initiation of steroid therapy. B) Patient 2: Enhanced T1
(upper row) and FLAIR (lower row) MRI images are displayed, corresponding to the indicated day of admission (d). White arrows point to areas of edema
surrounding the basal ganglia lesions. Days 1 and 34 were prior to steroid course #1 and #2, respectively. Day 24 and 66 were post steroid course #1 and
#2, respectively.
doi:10.1371/journal.ppat.1004884.g001
Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis
PLOS Pathogens | DOI:10.1371/journal.ppat.1004884 May 28, 2015 6 / 27
mental status and decreased enhancement and ventricular obstruction on brain MRI over the
following month (Fig 1B, Day 66, S1 Fig). The patient was transferred to the NIH on Day 85
and an attempt was made to reduce the prednisone dose to 25 mg, but mild mental status dete-
rioration and increased lesion size and edema on brain MRI (S1 Fig, Day 99) prompted an in-
crease in steroid dose after her lumbar puncture and immunophenotyping with mental status
improvement to a GCS back to normal (10 day GCS, pre: 14.3 +/-0.2 (SEM), N = 43; 10 day
post: 15.0 +/- 0.0, N = 28; p< 0.01). Subsequently, amphotericin B was replaced by fluconazole
and steroids were slowly tapered over the following 8 months as the cryptococcal antigen de-
clined and was accompanied by normalization of activities. Fortunately, this patient made
marked recovery with ability to resume her activities of daily living but with some residual
memory deficits.
Study subjects
Subjects were participants in an observational cohort examining the host genetics and immu-
nology of cryptococcal disease in previously healthy, non-HIV infected adults. Written in-
formed consent was obtained and approved by the research ethics committee of the NIAID
institutional review board. Seventeen consecutively recruited patients with culture or biopsy-
proven CNS cryptococcal disease were studied. Severe disease was present in all 17 and was de-
fined as patients demonstrating significant deteriorations in mental status (Glasgow Coma
Score, GCS< 15) despite standard fungicidal therapies with amphotericin B-based regimens
and 12 of 17 required ventriculoperitoneal shunting for persistently elevated intracranial pres-
sures. The s-CNS patients had demonstrated initial responses to antifungal therapy as evi-
denced by improvement in clinical, CSF, and radiologic parameters but subsequently worsened
along these parameters in the absence of microbiologic growth or another infectious process
after induction antifungals. As shown in Table 1, the 17 patients with s-CNS had median age of
54 years, with normal CD4+ (359-1565/μl) and CD8+ (178-853/μl) T lymphocyte counts. Pa-
tients were studied while undergoing active treatment with anti-fungal regimens and had nega-
tive CSF cultures at the time of analysis and remained negative throughout treatment.
Fourteen required adjunctive prednisone (1 mg/kg/d or less) for control of cerebral edema,
which was either begun after immunophenotyping or was minimized prior to study as symp-
toms allowed with a median dose of 2.5 mg/d. Of note, all patients were screened for GMCSF
autoantibodies, but only two were positive (both s-CNS with C. gattii). Comparator groups
consisted of HD as well as a non-CNS infected cryptococcal cohort that submitted to a lumbar
puncture for research purposes.
s-CNS demonstrate intrathecal enrichment of innate and adaptive
immune cells with elevated levels of CSF NFL
Twelve color immunophenotyping panels quantified absolute numbers and proportions of 12
major subtypes of immune cells in the blood and CSF [26] in the 17 s-CNS patients and were
compared to 6 patients with previous fungal exposure leading to non-CNS disease as well as 11
HDs. These studies showed that s-CNS patients (Figs 2 and 3, right panels) had dramatic CSF
elevations in absolute numbers of all components of the innate and adaptive immune responses
as compared to non-CNS infected patients and HDs. Specifically, we observed significantly in-
creased absolute counts of HLA-DR activated CD4+ and CD8+ T lymphocytes and B lympho-
cytes in the CSF of s-CNS compared with non-CNS and HD (Fig 2). We also identified
significantly increased cytotoxic (CD56dim) and immunoregulatory (CD56bright) NK cells,
monocytes, and myeloid dendritic cells (MyDCs) in the CSF of s-CNS cases compared with
non-CNS cases and HD. Interestingly, there was a mild proportional decrease—albeit non-
Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis
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Fig 2. Immunophenotyping demonstrates increased absolute counts of CSF circulating activated HLA-DR+ CD4+ and CD8+ as well as—B-cells in
s-CNS patients. Absolute numbers and proportions of activated CD4+ and CD8+ T lymphocytes (HLA-DR+),—and B lymphocytes were assessed in fresh
CSF or blood by flow cytometry as described in Materials and Methods in patients with s-CNS disease (N = 17), non-CNS disease (N = 6), and healthy
donors (HD; N = 11). Proportions are calculated from the total CD45+ cells. *0.01p<0.05; **0.001p<0.01; ***0.0001p<0.001.
doi:10.1371/journal.ppat.1004884.g002
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Fig 3. Immunophenotyping demonstrates increased absolute CSF cytotoxic (CD56dim) and
immunoregulatory (CD56bright) NK cell populations, monocytes (Mono), and bothmyeloid (MyDC)
and plasmacytoid (PlDC) dendritic cells in CSF of s-CNS patients. Absolute numbers and proportions of
cell types were quantified by flow cytometry in CSF and blood as described in the Materials and Methods
section in patients with s-CNS disease (N = 17), non-CNS disease (n = 6), and healthy donors (HD; N = 11).
Proportions are calculated from the total CD45+ cells. *0.01p<0.05; **0.001p<0.01;
***0.0001p<0.001.
doi:10.1371/journal.ppat.1004884.g003
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significant—in monocytes and MyDCs in the CSF of s-CNS cases compared with non-CNS
cases and HD (Fig 3). Elevations in absolute granulocyte counts, attributed to steroid therapy
in some patients, were the other CSF abnormality that differentiated meningitis patients from
non-CNS patients and HD controls who did not receive steroids (Fig 3). However, no blood
immunophenotyping differences were noted among the groups except for increased absolute
counts and proportions of plasmacytoid dendritic cells (PlDCs) in the blood of non-CNS pa-
tients compared to s-CNS. Importantly, few CSF or blood immunophenotyping abnormalities
were observed in patients with non-CNS disease compared to HDs, the latter likely due to the
well-controlled nature of the disease and length of therapy.
In addition, CSF NFL levels were assayed, which are highly stable, neuron sensitive and spe-
cific biomarkers of axonal damage that fill the axon core and are released during neuronal
damage [27–29]. Interestingly, we found a more than 10-fold, statistically significant increase
in CSF NFL among s-CNS compared with non-CNS and with HD (S3 Fig). This suggests that
the increased inflammatory response in s-CNS disease is not a benign or protective response,
but is accompanied by elevated markers of neuronal damage.
Assessment of Ag-specific T cells reveals compartmentalization of anti-
cryptococcal Th1 T-cell immunity
Because we observed that cells of the adaptive immune system were elevated in the CSF of s-
CNS patients to a similar or even greater degree than cells of innate immunity, we tested if
these cells recognized cryptococcal antigens in a subgroup of 8 s-CNS patients, and if so,
whether they secreted IFN-γ, which is thought to confer protective immunity. Five patients
with non-CNS disease served as an appropriate comparator in this case, because they had been
exposed to the cryptococcal fungus and therefore would be expected to have memory and effec-
tor T cell responses specific for cryptococcal antigens. Since it is known that only memory/ef-
fector T cells routinely cross the blood-brain barrier to perform immunosurveillance functions
[30], intrathecal enrichment for cryptococcal-specific T cells have to be demonstrated against
individuals with pre-existing cryptococcal exposure to be biologically meaningful.
Because the immunodominant epitopes of Cryptococcus have not been well defined and the
s-CNS and non-CNS groups would require matching for major histocompatibility complex an-
tigens (MHC) for peptide-based assays, we instead utilized a novel methodology based on the
co-culture of autologous antigen (Ag)-loaded mature dendritic cells (mDCs) and T cells fol-
lowed by flow cytometry-based confirmation of antigen-specificity as previously described
[31]. In this assay, autologous DC’s phagocytose complex antigens (such as a cryptococcal ho-
mogenate) and select those epitopes that have the strongest binding to a patient’s MHCmole-
cules, thus mimicking in vivo conditions as much as possible. Furthermore, this assay allows
simultaneous read-outs of both CD4+ and CD8+ T cell responses, which is not possible in pep-
tide-based assays. In addition to cryptococcal cell homogenate, we used a more defined manno-
protein (MP) preparation, which has been used previously in HIV-related cryptococcal
infections to assess T-cell immune responses [11,32,33].
Using this approach, significant proliferative and secretory responses of CD4+ and CD8
+ cells were exhibited in response to DCs loaded with either cryptococcal homogenate or puri-
fied cryptococcal MP. Higher proliferation of blood CD4+ T lymphocytes co-cultured with
Ag-loaded DCs (Fig 4A, top left panel) was observed in the non-CNS patients compared with
the s-CNS patients. In contrast, higher proliferation of CSF CD8+ T lymphocytes (Fig 4A, bot-
tom right panel) was observed in the s-CNS patients after co-culture, suggesting a compart-
mentalization of the proliferative responses. Proliferation of CSF CD4+ cells was also observed
in s-CNS patients compared to the unstimulated cells from the same patients, but was not
Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis
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statistically greater than the non-CNS patients in this small cohort of patients. In addition, in-
creased IFN-γ secretion (Fig 4B, right panel) but not TNF-α was observed in both CD4+ and
CD8+ T cells from CSF of s-CNS patients compared to those from non-CNS patients. These
data suggest an ongoing compartmentalized antigen-specific Th1 response in the CSF.
Interestingly, responses to homogenate were greater than to that of the purified MP. MP
was made from an acapsular strain (cap67) having serotype D background and serotype D is
unusual in the U.S., whereas the homogenate was derived from H99, a serotype A strain—a
Fig 4. Ex vivo cryptococcal antigenic stimulation by pulsed autologous mature dendritic cells (mDCs) co-cultured with T lymphocytes from CSF or
blood demonstrates compartmentalization of immune responses in a subgroup of 8 s-CNS and 5 non-CNS patients. (A) Sum of cytokine-producing
IFN-γ+, TNF-α+, and IFN-γ+/TNF-α+ CD4+ and CD8+ T lymphocytes (after mDC presentation of MP and Crypto). Events are normalized to fluorescent
beads. B) IFN-γ production of activated CD4+ and CD8+ T lymphocytes after Crypto presentation by mDCs. Tc = T lymphocyte; Crypto = glass bead-
fractured, heat-killedC. neoformans strain H99; MP = C. neoformansmannoprotein; No Ag = no antigen (un-loaded mDCs). Open circles and bars are
representative of non-CNS (Pulmonary) cases, filled circles and bars of s-CNS (CNS) cases. Error bars specify minimum to maximum values.
*0.01p<0.05; **0.001p<0.01; ***0.0001p<0.001.
doi:10.1371/journal.ppat.1004884.g004
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clinical strain that is much more prevalent in the U.S.. In addition, MP is a purified component
of the fungus, which undergoes mannosylation [34,35], but does not contain cell wall carbohy-
drates, lipids, or nucleic acids found in homogenates that could boost responses due to toll-like
receptor (TLR) and c-lectin receptor (CLR) stimulation [36,37].
CSF soluble biomarkers suggest a robust Th1 response within the
intrathecal compartment of s-CNS patients
To further assess CSF functional responses, expression of representative soluble cytokine and
chemokines was determined among patients at the time of the cellular studies described in
Fig 3. CSF from s-CNS patients demonstrated significantly increased intrathecal production of
soluble IFN-γ, as well as interferon-induced IL-18, and chemokines CXCL10, as compared to
the non-CNS patients or HD (Fig 5a–5c). Although IL-6 induces c-reactive protein (CRP) in
the liver via the JAK/STAT pathways [38], no correlation was noted between serum CRP and
CSF IL-6 and there was no difference between serum CRP of CNS vs. non-CNS cases (Table 1).
The pro-inflammatory IL-6 (Fig 5g) similarly demonstrated increased expression in CSF of s-
Fig 5. Intrathecal cytokine and chemokine profiles reveal elevated IFN-γ and related inflammatory responses in cryptococcosis patients with s-
CNS disease compared with non-CNS disease and healthy donors (HD). CSF was analyzed using Luminex assays according to the Materials and
Methods section. (a) IFN-γ, (b) CXCL10 (IP-10), (c) IL-18, (d) TNF-α, (e) IL-10, (f) IL-4, (g) IL-6, (h) IL-13, (i) MCP-1/CCL2, (j) MIP-1α/CCL3, (k) MCP-3/CCL7,
and (l) MIP-3β/CCL19. Cytokine and chemokine concentrations were expressed as log10 picogram per milliliter (pg/ml) in s-CNS and non-CNS patients and
HD. IL-8, GM-CSF, M-CSF, IL-12p40, IL-17, and IFN-α2 are not shown (without statistically significant differences among case groups). Error bars represent
minimum to maximum values. *0.01p<0.05; **0.001p<0.01; ***0.0001p<0.001; ****p<0.0001.
doi:10.1371/journal.ppat.1004884.g005
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CNS patients as was the cytokine, IL-10 (Fig 5e). Interestingly, TNF-α levels were not signifi-
cantly elevated (Fig 5d), consistent with the observed lack of increased TNF-α cellular produc-
tion by T-cells incubated with ex vivo antigen-stimulated DCs described in the previous
section and/or a functionally insufficient immune response from monocytes. S-CNS patients
also produced significantly elevated levels of the chemokines CCL2 (monocyte chemoattrac-
tant protein-3 [MCP-1], CCL3 (macrophage inflammatory protein-1α [MIP-1α]), CCL7
(monocyte chemoattractant protein-3 [MCP-3]), and CCL19 (macrophage inflammatory pro-
tein-3β [MIP-3β]), compared to HD (Fig 5i–5l). Since these chemokine ligands are chemotactic
for monocytes and T-lymphocytes, but CXCL10 is chemotactic only for CXCR3+ T-lympho-
cytes, one can infer the relative infiltration of monocytes compared to T-cells in the CSF based
on the ratio of CCL3/CXCL10, for example. Statistically significant decreased CCL2/CXCL10
and CCL3/CXCL10 among s-CNS compared with HD and CCL19/CXCL10 among s-CNS
compared with non-CNS and with HD corroborated decreased circulating monocyte CSF pop-
ulations vis à vis T lymphocyte trafficking to the CSF (S2 Fig). In addition, non-CNS patients
had significantly more detectable intrathecal IL-4 than s-CNS and HD (Fig 5f). These data
again suggest a robust Th1-polarized response with evidence of active inflammatory activation
within the intrathecal compartment.
Brain Immunohistochemistry in 2 brain biopsies and an autopsy series of
non-HIV-related patients with s-CNS disease demonstrates a
predominance of tissue macrophages accompanied by T lymphocytes
Analysis of the intrathecal compartment by CSF sampling may be limited due to differences be-
tween CSF circulating and tissue-penetrant cells. Thus, brain biopsies obtained from two of the
s-CNS patients as part of their diagnostic workup were examined using CD68, CD163, CD3,
CD4 and CD8 staining. These biopsies were done prior to steroid therapy. Both biopsies dem-
onstrated a predominance of CD68 positive monocyte/macrophages as well as the presence of
T-cell infiltration in the region of the biopsy (Fig 6), suggesting that reductions in CSF circulat-
ing monocytes may be due to tissue infiltration of this cell population in these patients. Inter-
estingly, while macrophages underwent tissue infiltration, iNOS and CD200R1 staining in one
of the biopsy specimens that contained sufficient tissue for more detailed analysis suggested
the macrophages underwent a non-protective alternative activation and less than 1% of fungal
cells were observed to be co-localized with macrophages, suggesting poor phagocytic function
during cryptococcal brain infection of this patient (Fig 6B).
Because of the limited availability of brain tissue in the live s-CNS cohort, an analysis of
NIH clinical center records (1957–2009) was conducted to identify non-AIDS infected patients
who died of cryptococcal meningitis by autopsy (Table 2). All patients were treated with am-
photericin-based regimens but two had had Hodgkin’s disease. Review of the autopsy report al-
lowed exclusion of patients with known comorbidities such as sarcoidosis, HIV or other co-
infections and inclusion of patients who died with cerebral herniation. During his neurological
decline, one patient also developed bronchopneumonia from aspiration. Characteristics of the
five s-CNS patients who died of cryptococcal meningoencephalitis are listed in Table 2. In
these patients, immunohistochemistry (IHC) showed extensive leptomeningeal and Virchow-
Robin space infiltration of CD68 and CD163 macrophages as well as the presence of CD3,
CD4, and CD8 T lymphocytes (Fig 7).
This suggests that the apparent decrease of myeloid cells in the CSF obtained in the present
cohort may have been due to relative increases in monocyte/DC infiltration of the brain paren-
chyma. This would appear to be an effective monocyte response. However, further analysis of
the autopsy specimens using fluorescent probes of tissue sections (Fig 8) indicated that the
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majority of the patients (4/5) demonstrated an M2 non-protective bias (CD200R1+) to their
CD68 positive monocyte/macrophages and calcofluor white fungal staining (Fig 9) demon-
strated poor uptake of fungal cells (< 1%) by these macrophage populations, regardless of the
monocyte activation status, consistent with the result in the biopsy specimen.
Discussion
The present study sought to comprehensively investigate innate and antigen-specific intrathe-
cal immunity of HIV-uninfected individuals with clinically severe, cryptococcal meningoen-
cephalitis to guide treatment strategies of a disease group with high mortality. These studies
were prompted by several potential conflicting issues in human cryptococcal disease including
1) a presumed T-cell defect in previously healthy patients based on paradigms developed with
HIV-associated infections, 2) the unknown contributions of microbiological control vs.
Fig 6. Brain biopsy specimens from patients with s-CNS cryptococcosis demonstrate macrophage
and T-cell tissue infiltration. A) Diagnostic specimens obtained from two s-CNS patients were stained with
macrophage markers CD 68 and CD163 and T-cell marker CD3. B) Immunofluorescence of brain biopsy of
one patient after staining with macrophage marker CD68 and M1marker (iNOS) and M2marker (CD200R1),
fungal stain, calcofluor white (CFW) and nuclear stain, 4',6-diamidino-2-phenylindole (DAPI). Magnification at
10 x with inset at 20x and scale bar set at 100 μm for 10x images.
doi:10.1371/journal.ppat.1004884.g006
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Table 2. Autopsy report summary of patients who died of severe CNS (s-CNS) cryptococcosis.
Autopsy # 1 2 3 4 5
Age (years), Race,
Sex
61y, W, F 21y,W, M 59y, W, F 35y, W, M 26y, W, F
Time from
Symptoms to Death
7 months 4 months 6 months 3 months 16.5 months
Time from
Treatment to Death
1 week 7 weeks 2 weeks 2 months 2.5 months
CAUSE OF DEATH respiratory failure due to
bilateral bronchopneumonia
decerebrate; grand
mal seizures
respiratory failure due to
brain compression
respiratory failure
due to CNS
depression
respiratory failure
TERMINAL
EVENT
Coma frequent confusion with
complete disorientation;
drowsy, obtunded noxious stimuli
withdrawal only
obtunded no
Brainstem
herniation signs
Cheyne-Stokes
respirations; small
divergent nonreactive
pupils
dilated pupils;
decerebrate
posturing;
hyperventilation
dilated pupils—>
deviation to left
Cheyne-Stokes
respirations
none
Deep tendon
reﬂexes (DTR);
Babinski's sign
hyperreactive DTR; absent
Babinski
normal DTR;
Babinski present
bilaterally
hyperreactive DTR;
Babinski present
bilaterally
hyperreactive
DTR; absent
Babinski
normal DTR; absent
Babinki
Spinal cord
compression sign
right hemiparesis left hemiparesis;
incontinence
incontinence clonus none
Cranial Nerve (CN)
Palsy
mild CN V left CN VI left CN VI, VII mild left CN VII none
Other
complications
right arm seizure papilledema papilledema papilledema with
retinal
hemorrhages
papilledema; left middle
and posterotemporal
lobe slowing on EEG
LP FINDINGS
WITHIN ONE
WEEK OF
DEATH
Spinal ﬂuid opening
pressure (mmH20)
330 270 300 330 120
Protein (mg/dl) 140 111 110 45 148
Glucose (mg/dl) 15 15 12 20 28
Cell count 11 (PMN predominant) 18 808 (403 PMN, 398
lymphs)
8 0
India ink positive positive positive positive negative
Culture
(Cryptococcus
neoformans*)
positive positive positive positive positive
CONCOMITANT
ILLNESS
Gastric ulcer; Dumping
syndrome post partial
gastrectomy; aspiration
pneumonia
Hodgkin's
lymphoma1
Diabetes mellitus Hodgkin's
lymphoma1
pneumonia; pulmonary
ﬁbrosis
TREATMENT Amphotericin B; no shunt Amphotericin B;
Prednisone 1mg/kg/
d**; no shunt
Amphotericin B;
emergency
decompression with
right lateral ventricle
catheter
Amphotericin B;
Prednisone 1mg/
kg/d**
Amphotericin B;
Prednisone 1mg/kg/d**
Cryptococcus autopsy cases for brain immunhistochemistry that have been collated according to the following inclusion criteria based on ﬁndings 1 week
prior to death: (1.) cryptococcal meningoencephalitis with or without dissemination (CSF India ink OR culture positive), (2.) Glasgow coma score < 8
for > 48 hours, (3.) presence of Babinski or other upper motor neuron signs OR seizure activity, and (4.) exclusion of competing risks.
PMN = polymorphonuclear leukocytes
*PCR of our parafﬁn embedded brain autopsy specimens revealed C. neoformans in all 5 autopsy specimens.
**tapered off by time of death
1 in remission
doi:10.1371/journal.ppat.1004884.t002
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dysfunctional/paradoxical immune responses in CNS disease and 3) the resultant ambiguities
as to whether microbiological control should be intensified in severe cases with antifungals or
augmentative cytokines such as IFN-γ or adjunctive immune suppression with steroids or
other agents. A dramatic clinical and radiological response in two patients to steroids further
provided a rationale for these studies, focusing on subsequent, consecutive patients recruited to
the NIH clinical center with CNS cryptococcosis. Likely due to referral bias, all 17 were severely
affected with altered mental status, suggesting a label of s-CNS disease to indicated the severity
of the cohort. The clinical process appears to be quite long lasting, with clinical severity and
MRI brain findings following the clearance of cryptococcal antigen over many months or a
year as described in S1 Fig.
Interestingly, despite an expectation of low T-cell function, this cohort of s-CNS disease,
displayed intrathecal expansion and activation of cells of both innate and adaptive immunity
including HLA-DR+ CD4+ and CD8+ cells and NK cells. These expanded CSF T cells were en-
riched for cryptococcal-antigen specific CD4+ and CD8+ T cells that are critical in protection
from the fungus [39], secreting the protective cytokine, IFN-γ [40] as well as a lack of highly el-
evated CSF levels of typical T-cell specific Th2 cytokines IL-4 and IL-13 (IL13 was barely
Fig 7. Brain immunohistochemistry staining of brain autopsy specimens from patients who died of s-CNS cryptococcosis demonstrate
macrophage and T-cell tissue infiltration. Autopsy specimens frommeninges (#1, #2), Virchow-Robin space (#3, #4) or within brain parenchyma (#2, #5)
were stained with macrophage markers CD 68 and CD163 and T-cell markers CD3, CD4 and CD8. Magnification at 10x with inset at 20x and scale bar set at
100 μm for 10x images.
doi:10.1371/journal.ppat.1004884.g007
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significant)[41], or typical Th17 cytokines IL-17 or GM-CSF (also not shown). Animal studies
have suggested that IL-17 is not required for classical activation of macrophages in cryptococ-
cal infections [42] and may not be as important as Th1-type responses [43]. Because patients
with s-CNS had more than 1000-fold increased numbers of CSF T cells, in comparison to sys-
temic Cryptococcus disease controls (i.e., non-CNS) and HDs, lack of prototypic Th2 and Th17
cytokines in the CSF of these patients is highly informative and in our opinion represents
strong evidence for Th1 skewing of infiltrating T cells. This Th1-biased response was unexpect-
ed as such a response is thought to be protective against C. neoformans in both mouse studies
[44] and human experience where T-cell defects from HIV/AIDS [11] or during solid organ
transplant conditioning [45], predispose to cryptococcal infections. Interestingly, Jarvis et al
noted different antigen-specific functional T cell phenotypes in HIV-infected patients with
cryptococcal meningitis and another intracellular pathogen—tuberculosis [11]. These repre-
sent important findings and suggests that the clinical worsening in Patient 1 (Fig 1) after re-
combinant IFN-γ therapy may have been due to exacerbation of this paradoxical inflammatory
state and suggests caution in using this suggested approach [9,10] in non-HIV-related s-CNS
cryptococcal disease. Indeed, we found that this inflammatory response was accompanied by a
more than 10-fold elevation in CSF NFL, a biomarker of axonal damage in diverse neurological
disease [27,28] and suggests that the paradoxical inflammatory response results in ongoing
neurological damage. Thus, the present study represents a critical application to human disease
whereby too much of an immune response can be detrimental by virtue of host-induced dam-
age [15,16].
Fig 8. Brain immunofluorescence of autopsy specimens from patients who died of s-CNS cryptococcosis demonstrates macrophage and T-cell
tissue infiltration. Fluorescent macrophage markers (CD68) and M1marker (iNOS) and M2 marker (CD200R1) were used to stain cells within the peri-
vascular brain parenchyma. DAPI was used for nuclear localization. Magnification at 10x with inset and scale bar set at 100 μm for 10x images.
doi:10.1371/journal.ppat.1004884.g008
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Interestingly, we observed this aggravated immune response in patients infected with either
C. neoformans or C. gattii, the latter of which is reported to cause increased inflammatory re-
sponses in mice [46] and human patients [14]. This paradoxical immune response in non-
HIV-infected individuals bears resemblance to that of cIRIS in HIV/AIDS that occurs after ini-
tiation of anti-retroviral therapy (ART). In cIRIS, patients who initially show a clinical and mi-
crobiological response to anti-fungal therapy develop, after initiation of ART, clinical
worsening of meningitis symptoms including deteriorations in mental status or increased
lymphadenopathy, cutaneous lesions or pulmonary nodules, despite continued negative fungal
cultures [47]. Immunologic studies of HIV-related cIRIS identified within the blood compart-
ment, a similar Th1-driven response consisting of enrichment of CD4+ and CD8+ T cells coex-
pressing activation markers CCR5 and CXCR3 with detection of IFN-γ-dependent chemokines
such as CXCL10 [48]. Within the CSF compartment, cIRIS is associated with elevations of
IFN-γ, TNF-α, G-CSF, VEGF, and eotaxin (CCL11) [49,50]. The paradoxical response is
thought to be due to a reversal of HIV-associated immune defects in the presence of continued
fungal antigen tissue burden [51].
However, a predominant difference between cIRIS and the intrathecal inflammatory re-
sponse of s-CNS patients in the present study may lie in the M2 skewing of CNS-tissue
Fig 9. Brain immunofluorescence of autopsy specimens from patients who died of s-CNS
cryptococcosis. Fluorescent macrophage marker (CD68) and fungal marker calcofluor white (CFW) was
used to stain cells within the peri-vascular brain parenchyma. Magnification at 10x with inset and scale bar
set at 100 μm for 10x images.
doi:10.1371/journal.ppat.1004884.g009
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infiltrating macrophages in the latter group which is a non-protective response in animal mod-
els of cryptococcosis [52]. This M2 phenotype was suggested by the predominance of CD68+,
CD200R1+ monocytes found in our autopsy and biopsy marker studies and was also corrobo-
rated by a lack of increased CSF levels of IL-12p40 and TNF-α as well as elevated CSF levels of
IL-10 in the s-CNS patients. This M2 skewing was present regardless of the presence of steroids
and was present early in the course of the disease as demonstrated in the diagnostic biopsy #1.
It is unclear whether the predominant intrathecal cellular source of these differentially-express-
ed cytokines are T cells or monocytes/macrophages, which are traditionally robust sources of
TNF-α and IL-10 [53]. Given the Th1 bias of T cells in the present study, the tissue infiltrating
M2 cells are a potential source of IL-10 and the M2 bias likely reduced production of fungal
protective TNF-α [54,55]. This latter defect may also explain the critical lack of fevers in these
patients, which is a major factor leading to diagnostic delays in this patient population.
A second main difference of the non-HIV response from cIRIS is that no immunostimula-
tory or immune restoring interventions were required to produce the paradoxical immune re-
sponse in the HIV-uninfected individuals. The fact that clinical deterioration in the present
series occurred, usually after a month of fungicidal therapy and with negative CSF cultures sug-
gests that liberation of fungal antigens during therapy may have induced intrathecal activation
of antigen-specific T cells. Indeed, intact C. neoformans cells prior to therapy are protected
from immune recognition by an immune suppressive polysaccharide capsule [56], an extracel-
lular laccase [57] and components of the fungal cell wall [58], lysis of which results in release of
intracellular fungal antigens.
Because the presented functional studies are extremely laborious, require large amounts of
fresh biological samples and the targeted patient population is rare and includes very sick sub-
jects, a natural limitation of our study is its small sample size and limited sample numbers per
patient. In addition, the variability in treatment duration and steroid use for cerebral edema
may make heterogeneity a source of concern, though the significant findings despite this are
noteworthy. The present study was thus an important first step in the description of the im-
mune response in this population, but did not attempt to use specific immune responses to
stratify outcomes or follow the evolution of the disease, although elevated Th1 responses were
identified over a prolonged time frame as long as symptoms and antigen persisted. The limita-
tion of the patient population to those previously healthy helped to add a measure of uniformi-
ty to the population, but may limit the application to more immunosuppressed patients such
as those undergoing transplant conditioning. In addition, referral bias likely led to a higher dis-
ease severity that may not be applicable all previously healthy patients with CNS disease. How-
ever, the expected high mortality of this group makes its study highly compelling for
suggesting studies to improve therapy. In addition, it is important to note that the results here
represent patients that deteriorate during effective fungicidal therapy and should not be applied
to clinical issues on initial presentation when microbial control may be more important.
Despite the robust Th1 bias and inflammatory response, the immune response appeared to
be ineffective to prevent or clear the fungus. Recent data demonstrating the relative rarity of
non-HIV cryptococcal disease [5] despite high rates of exposure [59] also support a defective
host response. Data acquired in the present study all point towards a defective innate immuni-
ty, and, more specifically, defects of the myeloid lineage. We identified poor proportional
monocyte recruitment to the circulating pool of the CSF cells and a predominant non-protec-
tive M2 response in most of the autopsy specimens, as well as an inability to phagocytose the
fungus in situ. This is consistent with our recent data demonstrating the presence of a STAT5
phosphorylation-blocking GM-CSF autoantibody in a subset of patients with cryptococcal dis-
ease [25,60] and suggest that future targeted studies should focus on the mechanistic assess-
ment of cells of myeloid lineage, including evaluation of phagocytosis [61], oxidative burst [62]
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and antigen processing [63] important to cryptococcal defense. In conclusion, the present
study suggests that an ineffective macrophage response in the setting of intact T-cell activation
has the potential to cause increased susceptibility of the patient to the fungus and severe CNS
disease after initiation of effective anti-fungal therapy. We infer that there may be either intrin-
sic or extrinsic defects at the immune synapse between Th1 cells and antigen presenting mono-
cytes or further downstream that lead to a paradoxical M2 polarization. These studies also
provide pathophysiological support for studies of adjunctive immunosuppressive trials in se-
vere non-HIV related cryptococcal disease to control paradoxical immune responses after sus-
tained microbiological control in a CNS fungal disease with high mortality.
Materials and Methods
Ethics statement
The National Institute of Allergy and Infectious Diseases (NIAID) Institutional Review Board
(IRB) approved this study under NIAID Protocol #93-I-0106. The National Institute of Neuro-
logical Disorders and Stroke (NINDS) approved the study under NINDS Protocol #09-N-0032.
All subjects provided written informed consent directly or via their durable power of attorney,
after obtaining National Institutes of Health (NIH) Bioethics consultation.
Participants and patient clinical data
We studied 17 consecutive patients with cryptococcal meningitis who were all found to exhibit
characteristics of severe CNS cryptococcal disease (s-CNS) from an ongoing recruitment co-
hort of 80 patients with cryptococcal disease in previously healthy individuals without known
immunocompromising conditions (HIV 1/2, HTLV-1, and Hepatitis B and C seronegative in-
dividuals, idiopathic CD4 lymphopenia (ICL), those without antecedent known malignancy,
liver/renal failure, sarcoidosis, systemic autoimmune disorders, and recipients of transplants or
immunosuppressive medications such as corticosteroids, calcineurin inhibitors, etc. . .) S-CNS
was defined as persistent or deteriorating mental status changes (Glasgow Coma Score,
GCS< 15) despite adequate amphotericin B-based antifungal therapy (6 weeks) and all had
repeated negative CSF cultures after 6 weeks of therapy. Comparator groups were selected as
patients within the larger cohort with non-CNS disease including 5 with pulmonary and 1 with
isolated spinal bone disease and 11 healthy donors (HD). Diagnosis was made by CSF India
ink stain and/or culture, or a positive mucicarmine stain and/or culture from a biopsy site or a
positive cryptococcal antigen testing (Meridian Cryptococcal Latex Agglutination System; Me-
ridian Bioscience), according to previous case definitions [64]. We performed an extensive
chart review of 17 s-CNS cases and 6 non-CNS cases and tabulated pertinent clinical informa-
tion related to the timeline of their infection in Table 1. Mental status was evaluated as Glasgow
Coma Score (GCS) by clinical staff of the NIH clinical center during 24 h monitoring, using a
standardized protocol and expressed as a 10 day average +/- SEM of all measurements. (http://
www.commondataelements.ninds.nih.gov/Stroke.aspx#tab=Data_Standards). Evaluations
were performed 3–4 times per day between the hours of 8 am and 11 pm.
Ex vivo peripheral blood and CSF immunophenotyping
Immunophenotyping of peripheral blood cells was performed within 60 min of ex vivo collec-
tion on anticoagulated blood after osmotic lysis of erythrocytes. CSF samples were placed on
ice immediately after collection. Within 15 min of collection, the CSF (usually 20 ml) was spun
and cell pellets were resuspended in 400 ml ice-cold X-Vivo media (Lonza, Alpharetta, GA).
The Fc receptors of cells were blocked by using 2% immune serum globulin to prevent non-
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specific activation. A 12-color immunophenotyping panel to distinguish 12 leukocyte cell types
was adapted using the markers in S1 Table from that previously described [26].
Isolation of peripheral blood mononuclear cells (PBMCs) and generation
of dendritic cells (DCs)
120 ml of heparinized blood samples were collected eight days before the scheduled lumbar
puncture (LP). Isolation of PBMCs and generation of DCs with GM-CSF, IL-4 and 5% human
serum were performed as described previously [31]. On day six of culture, immature DCs were
co-incubated overnight with the following antigens (Ag’s) and subsequently stimulated for 48
hours: mannoprotein (MP), prepared as described [32], and cryptococcal heat-killed suspen-
sion (Crypto; both 5 μg/ml) with maturation factors, TNF-α, IL-1B, IL-6 and PGE2. Crypto-
coccal heat killed suspension was prepared by glass-bead fractured C. neoformansH99 strain
ATCC 208821 ( = CBS8710) that had been heated at 90°C for 30 min and the suspension al-
lowed to settle overnight at room temperature. The suspended material was recovered and
quantified by protein analysis by using a BioRad assay according the manufacturer’s directions
(BioRad, Hercules, CA). Optimal Ag-concentrations were determined in preliminary experi-
ments by titration (i.e. inducing T cell proliferation without evidence of toxicity).
Co-culture of Ag-loaded mature dendritic cells (s) and T cells
At the day of LP (day eight of culture) peripheral T cells were purified from frozen PBMCs by
negative selection (Miltenyi Biotech, San Diego, CA). Peripheral and CSF T cells were then cul-
tured in round bottom 96 well plates with autologous Ag-loaded mDCs (3x103 mDCs: 3x103 T
cells) in a total volume of 100 μl X-Vivo media (Lonza) at 37°C, 5% CO2. After seven days of
proliferation, T cells were re-stimulated overnight for the intracellular cytokine staining (ICCS)
with twice as much newly differentiated, identically loaded autologous mDCs as used for the
first co-culture in presence of Brefeldin A and monensin (eBioscience). Ag-specificity was de-
tected by flow cytometric analysis of cytokine-producing CD4+ and CD8+ T cells.
Flow cytometric analysis of surface markers and intracellular cytokines
T cells were analyzed for the surface markers CD3 (UCHT1), CD4 (RPA-T4), and CD8 (SK1),
and intracellular expression of GM-CSF (GM2F3), IL-17 (eBio64DEC17), TNF-α (MAb11)
and IFN-γ (B27; BD Biosciences, San Jose, CA and eBioscience). Data were analyzed with BD
FACS Diva 6.1 (BD Biosciences).
Absolute numbers of cytokine-producing cells were determined by normalization with APC
beads. For inter-patient comparison we standardized the number of cytokine positive events
(i.e. IFN-γ+, TNF-α+, and double positive events) to 1000 beads each.
Mean fluorescence intensities (MFIs) of cytokine-secreting CD4+ and CD8+ T cells were de-
termined by subtraction of the respective isotype controls. Negative values were adjusted
to zero.
CSF cytokine and NFL quantification
After lumber puncture, CSF samples were centrifuged at 300 g and stored at -80C until analysis.
CSF from unstimulated CSF flow cytometry experiments on s-CNS, non-CNS, and HD above
were analyzed using a sandwich-enzyme linked immunosorbent assay (Luminex, Bio-Rad).
After including standards, we assayed for intrathecal evidence of IL-4, IL-6, IL-8/CXCL8, IL-10,
IL-12p40, IL-13, IL-17, IL-18, IP-10/CXCL10, IFN-α2, IFN-γ, TNF-α, MCP-1/CCL2, MIP-1α/
CCL3, MCP-3/CCL7, MIP-3β/CCL19, M-CSF, and GM-CSF. Detected amounts were expressed
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in log10 picogram/milliliter (pg/ml). CSF levels of NFL were measured according to the manu-
facturer’s instructions using a sandwich ELISA method (Uman Diagnostics AB; Umea Sweden).
Brain immunohistochemistry and macrophage polarization studies
Brain immunohistochemistry (IHC) on five patients who died from s-CNS cryptococcal dis-
ease (and two biopsy specimens from live patients with s-CNS disease) were collated. The in-
clusion criteria for autopsies were based on findings one week prior to death: (1.) cryptococcal
meningoencephalitis with or without extraneural infection (CSF India ink or culture positive
andWBC> 50 and opening pressure> 200 mm); (2.) Glasgow Coma Score< 8 for> 48
hours; (3.) the presence of Babinski or other upper motor neuron signs or seizure activity; and
(4.) exclusion of competing causes of death. Chromogenic staining using horse radish peroxi-
dase-conjugated secondary antibody for T lymphocyte markers (CD3 [F7.2.38 clone], CD4,
and CD8) and macrophage markers (CD68 [KP1 clone] and CD163) was performed (Dako
North America, Carpenteria, CA) and representative images captured using Leica Software at
10x and 20x magnification. Polarization of macrophages was performed on autopsy and biopsy
specimens using double immunofluorescence staining according the manufacturer’s directions
(Abcam). M1 was characterized by CD68/iNOS expression and M2 was identified by CD68/
CD200R1 co-staining as described [65]. Calcofluor white was used to stain cryptococcal cells
and DAPI (4',6-diamidino-2-phenylindole) for nuclear staining. To detect cryptococcal DNA
in the paraffin-embedded specimens, a DNA extraction was performed by using the black-
PREP FFPE DNA Kit (Analytik Jena, Jena, Germany) with an additional lyticase treatment.
Real-time PCRs were performed on the extracts to detect cryptococcal DNA, and specifically
C. gattii, as described previously [66,67].
Statistics
Ten day GCS averages were determined by averaging scores over successive 10 day intervals
(N> 20 determinations), beginning on the first day of admission among each of two illustrated
s-CNS patients. We used repeated measures ANOVA to account for the inter-correlated GCS
values to determine statistical significant changes 10 days before and 10 days after corticoste-
roid therapy. For the CSF cytokine/chemokine analysis among s-CNS, non-CNS, and HD, the
non-parametric Kruskal-Wallis test was utilized, controlling for multiple comparisons between
each group using the Dunn procedure [68]. For NFL chain analysis, since we were interested in
assessing only neuronal damage using s-CNS as the comparator, we performed a non-paramet-
ric Mann-UWhitney test adjusting for comparison between s-CNS vs. non-CNS and s-CNS
vs. HD using a Bonferroni correction. CSF cytokine, chemokine, and NFL analysis was per-
formed using PRISM (version 6.0, Graphpad Software, La Jolla, CA).
For immunophenotyping assays, one-way ANOVA (analysis of variance) was performed to
explore the association of explanatory variable (diagnosis: s-CNS, non-CNS, and HDs) with 56
response variables which are the absolute numbers or proportions of adaptive and innate im-
mune cells collected from CSF and blood staining samples. Since most of these response vari-
ables did not follow a normal distribution, Box-Cox transformation was applied (log-
transformation for most of the variables) prior to ANOVA. Tukey’s method was used for pair-
wise multiple comparisons. P-values were adjusted for multiple testing. A two sample t-test
was used to test the difference between Ag-specific T cell proliferation and between MFIs in
the non-CNS and s-CNS cohorts. Peripheral and intrathecal T cells were analyzed separately
for CD4+ and CD8+ T lymphocytes. Zero MFI values were treated as missing values. Log
transformation was applied to all outcome measures. These statistical analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC) with p0.05 considered a significant level.
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Supporting Information
S1 Fig. Steroid-responsiveness of refractory cryptococcal meningitis in patient #2 from Fig
1. Top panel, Enhanced MRI T1 and FLAIR weighted images corresponding to hospital Day.
Lower panels, indicated steroid dosage (black line) and CSF cryptococcal latex antigen titer ().
(TIF)
S2 Fig. CSF ratios of CCL2/CXCL10, CCL3/CXCL10, CCL7/CXCL10, and CCL19/CXCL10
(supplement to Fig 5). Depicted CSF chemokine ratios determined from data shown in Fig 5
of the CSF circulating pool of s-CNS patients compared with non-CNS patients and healthy
donor controls (HD). Error bars represent minimum to maximum values. 0.01p<0.05;
0.001p<0.01; 0.0001p<0.001; p<0.0001.
(TIF)
S3 Fig. NFL analysis reveals significantly increased NFL levels in CSF of s-CNS compared
with non-CNS or HD (supplement to Fig 5). CSF NFL levels assayed from CSF as described
in Materials and Methods. 0.01p<0.05; 0.001p<0.01.
(TIF)
S1 Table. Optimized combination of flourochrome-conjugated antibodies used to quantify
12 subpopulations of immune cells.
(DOCX)
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